Drugs / HRS-5346
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07619443 | Jul → Sep 2026 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06441227 | Jun 2024 → Jan 2025 | lip disorder | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07614984 | Jun 2026 → Oct 2027 expected | lipoprotein, variant of beta | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06816264 | Feb → Sep 2025 | — | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-5346 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06441227 ↗ |
| Known as | MK-7262 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07614984 ↗ |
| Route | Oral | “Multiple Oral HRS-5346 Tablets” NCT06441227 ↗ |